National Survey of Precision Medicine in Cancer Treatment
Note: This is a completed initiative.
The National Survey of Precision Medicine in Cancer Treatment was the first nationally representative survey of oncologists about the current practice of precision medicine in cancer treatment.
The Survey was fielded in 2017 to better understand how oncologists use genomic testing to inform treatment recommendations; their confidence in using genomic test results to guide care; as well as key barriers, drivers, and other factors that influence their use of genomic testing in clinical practice. A nationally representative sample of 1,281 medical oncologists, hematologists-oncologists, and hematologists practicing in the United States participated in the survey.
The National Survey of Precision Medicine in Cancer Treatment was sponsored by the National Cancer Institute, with support from the American Cancer Society and National Human Genome Research Institute.
Please acknowledge the National Cancer Institute National Survey of Precision Medicine in Cancer Treatment if you use the survey in your research.
Please refer to the following publications for additional information about the National Survey of Precision Medicine in Cancer Treatment.
Freedman AN, Klabunde CN, Wiant K, Enewold L, Gray SW, Filipski KK, Keating NL, Leonard DGB, Lively T, McNeel TS, Minasian L, Potosky AL, Rivera DR, Schilsky RL, Schrag D, Simonds NI, Sineshaw HM, Struewing JP, Willis G, de Moor JS. Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCO Precision Oncology 2018 :2, 1-13 [Full Text]
Wiant K, Geisen E, Creel D, Willis G, Freedman A, de Moor J, Klabunde C. Risks and rewards of using prepaid vs. postpaid incentive checks on a survey of physicians. BMC Med Res Methodol. 2018 Oct 11;18(1):104. doi: 10.1186/s12874-018-0565-z. [Abstract]